Vulvar lichen sclerosus: a comparison of the short-term topical application of clobetasol dipropionate 0.05% versus mometasone furoate 0.1%.

Objective: To compare the efficacy of the short-term application of clobetasol propionate 0.05% (CLB) and mometasone furoate 0.05% (MMF) in the treatment of vulvar lichen sclerosus (VLS).

Electrodiagnostic functional sensory evaluation of patients with generalized vulvodynia: a pilot study.

Objective: To objectively evaluate vulvodynia by the current perception threshold (CPT) neurometer.

Methods: Neuroselective CPT measures of the pudendal nerve were obtained at the perineum by a neurometer (Neurotron, Inc, Baltimore, MD), using constant alternating sinusoid waveform electrical stimulus at 2,000-, 250-, and 5-Hz frequencies, in 20 healthy volunteers and 38 women with vulvodynia. The mean +/- SD CPT values in vulvodynia and healthy (control) women were analyzed with the Student t test.

Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users.

Purpose: The combination of hormone replacement therapy (HRT) and low-dose tamoxifen may retain the benefits while reducing the risks of either agent. We assessed the optimal biologic dose and schedule of tamoxifen in HRT users using surrogate end point biomarkers and menopausal symptoms.

Subjects And Methods: Two hundred ten current or de novo HRT users were randomly assigned to one of the following four arms: tamoxifen 1 mg/day and placebo/week, placebo/day and tamoxifen 10 mg/week, tamoxifen 5 mg/day and placebo/week, or both placebos for 12 months.

Capsaicin and the treatment of vulvar vestibulitis syndrome: a valuable alternative?

Objective: To assess the efficacy of topical capsaicin in the treatment of vulvar vestibulitis syndrome.

Study Design: Thirty-three consecutive women referred for vulvar vestibulitis syndrome were treated with topical capsaicin 0.05 %.

A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers.

Purpose: Oral conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA) increase breast cancer risk, whereas the effect of transdermal estradiol (E2) and MPA is less known. Fenretinide may decrease second breast malignancies in premenopausal women but not in postmenopausal women, suggesting a hormone-sensitizing effect. We compared the 6 and 12-month changes in insulin-like growth factor-I (IGF-I), IGF-binding protein-3 (IGFBP-3), IGF-I:IGFBP-3 ratio, sex-hormone binding-globulin, and computerized mammographic percent density during oral CEE or transdermal E2 with sequential MPA and fenretinide or placebo.